Vident Investment Advisory LLC Increases Position in AstraZeneca plc (AZN)

Vident Investment Advisory LLC grew its holdings in AstraZeneca plc (NYSE:AZN) by 30.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,090 shares of the company’s stock after acquiring an additional 16,137 shares during the quarter. Vident Investment Advisory LLC’s holdings in AstraZeneca were worth $2,426,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cambridge Investment Research Advisors Inc. boosted its position in shares of AstraZeneca by 11.2% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 52,667 shares of the company’s stock valued at $1,842,000 after acquiring an additional 5,299 shares during the period. Baird Financial Group Inc. lifted its position in AstraZeneca by 12.0% in the second quarter. Baird Financial Group Inc. now owns 56,959 shares of the company’s stock worth $2,000,000 after purchasing an additional 6,092 shares during the period. D.A. Davidson & CO. lifted its position in AstraZeneca by 59.8% in the second quarter. D.A. Davidson & CO. now owns 31,415 shares of the company’s stock worth $1,103,000 after purchasing an additional 11,753 shares during the period. Oppenheimer Asset Management Inc. lifted its position in AstraZeneca by 1.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 469,700 shares of the company’s stock worth $16,490,000 after purchasing an additional 7,895 shares during the period. Finally, FMR LLC lifted its position in AstraZeneca by 35.2% in the second quarter. FMR LLC now owns 20,243,181 shares of the company’s stock worth $710,738,000 after purchasing an additional 5,272,590 shares during the period. 15.97% of the stock is owned by institutional investors.

In other AstraZeneca news, major shareholder Plc Astrazeneca bought 246,666 shares of the stock in a transaction dated Friday, September 28th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $3,699,990.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

AZN has been the subject of several research reports. Zacks Investment Research cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, June 12th. Morningstar reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Tuesday, June 12th. ValuEngine raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, July 28th. Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Finally, Guggenheim began coverage on AstraZeneca in a research report on Monday. They issued a “buy” rating for the company. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. AstraZeneca has a consensus rating of “Buy” and an average price target of $38.94.

Shares of NYSE AZN opened at $38.35 on Tuesday. The firm has a market cap of $100.23 billion, a price-to-earnings ratio of 8.96, a P/E/G ratio of 2.10 and a beta of 0.58. AstraZeneca plc has a 52-week low of $31.99 and a 52-week high of $40.16. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.72 and a quick ratio of 0.54.

AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, July 26th. The company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.38. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The company had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the company posted $0.87 earnings per share. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, sell-side analysts predict that AstraZeneca plc will post 1.68 earnings per share for the current year.

The firm also recently announced a semiannual dividend, which was paid on Monday, September 10th. Stockholders of record on Friday, August 10th were paid a $0.45 dividend. The ex-dividend date of this dividend was Thursday, August 9th. This represents a dividend yield of 2.35%. AstraZeneca’s dividend payout ratio (DPR) is presently 20.56%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: How to Use the New Google Finance Tool

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply